Date: 2013-12-03
Type of information: Production agreement
Compound: antigen VAR2CSA for a placental malaria vaccine
Company: CMC Biologics (Denmark - USA) University of Copenhagen (Denmark)
Therapeutic area: Infectious diseases - Parasitic diseases
Type agreement: development
production
Action mechanism:
Disease: malaria
Details: * On December 3, 2013, CMC Biologics, a contract biopharmaceutical manufacturing and development organization with facilities in Copenhagen and Seattle, has announced that earlier this year it entered into an agreement with the University of Copenhagen for process development and cGMP clinical production of VAR2CSA for a placental malaria vaccine. The project is focused on developing a novel prophylactic vaccine designed to protect women against malaria during pregnancy. In 2003 Professor Ali Salanti and others at University of Copenhagen discovered the antigen VAR2CSA, which enable parasite accumulation in the placenta. The VAR2CSA molecule, developed by the University of Copenhagen, has the potential to significantly reduce the effects of the parasite. The vaccine antigen will be produced using ExpreS2ion Biotechnologies’ proprietary insect cell-based recombinant protein expression platform, ExpreS2.CMC Biologics will employ its technical expertise and experience in Process Development and cGMP manufacturing of Biopharmaceuticals in developing the vaccine and will provide cGMP grade clinical material for the upcoming clinical trials.
Financial terms:
Latest news:
